about
Non-alcoholic fatty liver disease: what the clinician needs to know.Role of inflammation and infection in the pathogenesis of human acute liver failure: Clinical implications for monitoring and therapyRole of NLRP3 Inflammasome in the Progression of NAFLD to NASHInvolvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosisThe Role of Innate Immunity in Alcoholic Liver DiseaseInteractions between Myc and Mediators of Inflammation in Chronic Liver DiseasesRoles and regulation of neutral sphingomyelinase-2 in cellular and pathological processesEndoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseasesA metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- miceMolecular Pathogenesis of NASHPathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal CellsCritical Roles of Kupffer Cells in the Pathogenesis of Alcoholic Liver Disease: From Basic Science to Clinical TrialsTargeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic SteatohepatitisHow Inflammation Impinges on NAFLD: A Role for Kupffer CellsPorcine circovirus: a historical perspectiveProgression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.STAT4 knockout mice are more susceptible to concanavalin A-induced T-cell hepatitis.Association of calf circumference with insulin resistance and non-alcohol fatty liver disease: the REACTION studyMicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1.Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease developmentBoth bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis.Metformin improves healthspan and lifespan in mice.Future therapy of portal hypertension in liver cirrhosis - a guess.Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects.CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.Differential regulation of protein expression in response to polyunsaturated fatty acids in the liver of apoE-knockout mice and in HepG2 cellsNLRP3 inflammasome activation is required for fibrosis development in NAFLD.HCC development is associated to peripheral insulin resistance in a mouse model of NASH.Hepatic inflammation and fibrosis: functional links and key pathways.IL-1 signaling in obesity-induced hepatic lipogenesis and steatosisA small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.Interleukin-1β enhances FasL-induced caspase-3/-7 activity without increasing apoptosis in primary mouse hepatocytes.Increased Sensitivity to Binge Alcohol-Induced Gut Leakiness and Inflammatory Liver Disease in HIV Transgenic Rats.Age-related sensitivity to endotoxin-induced liver inflammation: Implication of inflammasome/IL-1β for steatohepatitis.Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical studyLPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver diseaseDietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activationA pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet.Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease.
P2860
Q24563068-E7D43646-A99A-4AAC-AE17-0AC25D1B1869Q26741218-ACD289D4-6D79-44E6-8775-E2C46FBB0466Q26742102-B0CE5435-6E74-452E-A36B-42ADC52696FAQ26744390-73773AA6-2C63-41CA-8926-6CDC6D45D992Q26773226-D1321B32-249A-4342-B7D4-56844AC1ADBFQ26778328-73432492-411B-4A30-8430-2619973303FCQ27022944-60F228FF-8B78-465E-AD6F-B2E7B0FC10ABQ27027733-5E4EB45C-E249-4F0D-B535-BBB3F53E30A7Q27339224-F6CEB3AE-7894-4C89-BA17-68F14A78D248Q28071265-FFE4A5A1-0E5C-442D-BEB4-2F62F05C84D4Q28071596-2B04008B-1129-4208-B424-01716894D509Q28073542-D717FCA0-AB07-4FF6-8E8D-E1E7D9A211A8Q28077079-4C32AF62-C566-4AD1-9839-51A5D4A48456Q28083001-0C829904-3A61-4680-AA24-99C741357D9EQ28308000-E688A4FC-FB33-4DD8-8C66-989CEAF9CA82Q30375693-0A298784-35DD-4DFC-86A8-F428F32B7B14Q30416248-FCC68B98-5B20-4343-B12C-438802BEA532Q33708709-E76D12DE-2267-49AA-9B91-73C32E33FB33Q33742855-93487BDD-E76A-46C1-85F3-A03860257BBDQ33846263-7E98AE79-3950-4D8D-A6E1-2959032B249CQ33914071-22BEBB0D-8DB9-4613-AA01-5EDB81FE1CB6Q34214279-B43359A6-AA8C-46AA-9EBB-4E9C57F5A31FQ34360789-E5557674-745F-4673-BC8B-970B6649CE58Q34446521-87255D41-6C16-4C21-B383-BE2C8A17AF60Q34788651-C4B54F81-053E-4870-BB59-45099A278E24Q35086490-92A18F68-48F7-429E-BE8B-2093EFFB853FQ35092120-09FEA343-E940-417C-8663-8169AB5C343BQ35146713-4F4E9E29-1508-451D-A4F2-7971B69E69A3Q35172679-7F72ACCA-4032-4945-B57C-1533A9607C32Q35213917-061E9505-5EC4-4EF6-B250-4B212AD3A4AAQ35250416-38FFDBAA-0CFA-4F11-9709-9888D7084D47Q35350543-27E66BFD-33B5-44A6-98BF-5CAF15985B31Q35536427-0A09E93B-8915-40B9-9C06-D73687507E6FQ35814440-E97401E6-F40F-4FAF-A4AF-104E2FF2259EQ35935130-AB9FAF05-7EBD-448F-A047-6CFAA0CA3F4FQ35970399-F6721D4E-E029-4885-847F-F3918D208BAEQ36561514-4F65DBF4-EBBE-4C4D-9A60-4D3CB09805BCQ36621495-0CE4A571-C154-45EB-98A5-ADDF3783FCA5Q36796097-B8A2FFE3-B03C-4FF5-A53D-DB060DEE9AB3Q37205280-244F7DF3-BE4F-4544-8919-A2FAC8864132
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Inflammasomes in liver diseases.
@en
type
label
Inflammasomes in liver diseases.
@en
prefLabel
Inflammasomes in liver diseases.
@en
P1476
Inflammasomes in liver diseases.
@en
P2093
Gyongyi Szabo
Timea Csak
P304
P356
10.1016/J.JHEP.2012.03.035
P577
2012-05-23T00:00:00Z